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Abstract 
Studies have demonstrated that angiotensin II has been involved in immune and inflammatory responses 
which might contribute to the pathogenesis of immune-mediated diseases. Recent evidence suggests 
that oxidative stress may play a role in myocarditis. Here, we investigated whether olmesartan, an AT1R 
antagonist protects against experimental autoimmune myocarditis (EAM) by suppression of oxidative 
stress, endoplasmic reticulum (ER) stress and inflammatory cytokines. EAM was induced in Lewis rats by 
immunization with porcine cardiac myosin, were divided into two groups and treated with either 
olmesartan  (10  mg/kg/day)  or  vehicle  for  a  period  of  21  days.  Myocardial  functional  parameters 
measured by hemodynamic and echocardiographic analyses were significantly improved by the treat-
ment with olmesartan compared with those of vehicle-treated rats. Treatment with olmesartan at-
tenuated  the  myocardial  mRNA  expressions  of  proinflammatory  cytokines,  [Interleukin  (IL)-1β, 
monocyte chemoattractant protein-1, tumor necrosis factor-α and interferon-γ)] and the protein 
expression of tumor necrosis factor-α compared with that of vehicle-treated rats. Myocardial protein 
expressions of AT1R, NADPH oxidase subunits (p47phox, p67phox, gp91phox) and the expression of 
markers of oxidative stress (3-nitrotyrosine and 4-hydroxy-2-nonenal), and the cardiac apoptosis were 
also significantly decreased by the treatment with olmesartan compared with those of vehicle-treated 
rats. Furthermore, olmesartan treatment down-regulated the myocardial expressions of glucose reg-
ulated protein-78, growth arrest and DNA damage-inducible gene, caspase-12, phospho-p38 mito-
gen-activated protein kinase (MAPK) and phospho-JNK. These findings suggest that olmesartan pro-
tects against EAM in rats, at least in part via suppression of oxidative stress, ER stress and inflammatory 
cytokines. 
Key words: Experimental autoimmune myocarditis; oxidative stress; endoplasmic reticulum stress; 
inflammation; olmesartan 
Introduction 
Inflammation and autoimmunity are involved in 
many cardiac diseases. Myocarditis is an inflamma-
tory heart disease, and causes both acute and chronic 
heart failure as a result [1]. Some patients with myo-Int. J. Biol. Sci. 2011, 7 
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carditis show a fulminant course and die of intractable 
cardiogenic shock, and the treatment strategy for the 
disease is still unresolved [2]. One of the fatal sub-
types of myocarditis is giant cell myocarditis, and its 
etiology is considered to be related to autoimmunity 
[3, 4]. A model of rat experimental autoimmune my-
ocarditis (EAM) resembles human giant cell myocar-
ditis, and the recurrent form of EAM leads to dilated 
cardiomyopathy [3, 4]. EAM is induced by T cell ac-
tivation and the peak of inflammation is observed in 
the  heart  around  day  21  after  immunization  [5,  6]. 
Some  evidence  supports  a  role  of  cellular  immune 
mechanisms in the pathogenesis of myocarditis and 
subsequent DCM [7]. 
The  renin-angiotensin-aldosterone  system 
(RAAS) plays an important role in the pathogenesis of 
a variety of clinical conditions, including atheroscle-
rosis, hypertension, left ventricular (LV) hypertrophy, 
myocardial  infarction,  and  heart  failure  [8,  9].  As  a 
result, the RAAS represents a logical therapeutic tar-
get in the management of hypertension, renal disease, 
and  cardiovascular  disease.  Inhibition  of  the  RAAS 
with either angiotensin-converting enzyme inhibitors 
which block the formation of angiotensin II (Ang-II), 
the principal effector peptide of the RAAS or Ang-II 
receptor blockers (ARBs) block the deleterious effects 
of  Ang-II  at  the  Ang-II  type  1  receptor  (AT1R)  has 
been shown to be effective in lowering blood pressure 
and reducing cardiovascular mortality and morbidity 
in various at-risk patient populations. The effects of 
ARBs  in  the  treatment  of  hypertension,  congestive 
heart failure and myocardial fibrosis have been well 
analyzed in human trials, as well as animal models, 
and the focus of interest is now directed to its plei-
otropic effects, especially on inflammatory disorders. 
ARBs  have  also  been  reported  to  suppress  athero-
sclerotic lesions in animal models and patients with 
coronary artery disease or hypertension by modulat-
ing inflammatory responses [10-12]. 
Within the ARB class, olmesartan medoxomil is 
a  long  acting  AT1R  antagonist  approved  for  the 
treatment of mild to severe hypertension, alone or in 
combination with other agents. Olmesartan reduced 
the  production  of  reactive  oxygen  species  (ROS), 
suppressed  tissue  infiltration  of  macrophages,  and 
prevented  ventricular  hypertrophy  and  fibrosis  in 
hypertensive  Dhal  salt-sensitive  rats  with  advanced 
heart  failure  [13].  Tsuda  et  al  [14]  reported  that 
olmesartan synergistically attenuate atherosclerosis at 
least in part via inhibition of oxidative stress. Moreo-
ver,  olmesartan  is  therapeutically  effective  for  the 
treatment of patients with heart failure by reducing 
cytokines  and  oxidative  stress  through  its  an-
ti-inflammatory effects [12-14]. Thus the blockade of 
AT1  receptors  is  another  way  to  interrupt  the  ren-
in-angiotensin system (RAS). Recently olmesartan is 
shown to ameliorate EAM by the suppression of my-
ocardial  damage  and  inflammatory  events  in  the 
myocardium in addition to hemodynamic modifica-
tions [15, 16].  
Despite many reports show the beneficial effect 
of  olmesartan  in  cardiovascular  diseases  [12-18],  its 
effect on oxidative stress and endoplasmic reticulum 
(ER) stress is not known in rats with heart failure after 
EAM. Moreover no study has reported the effects of 
olmesartan on myocardial function by hemodynamic 
study, ER stress and MAPK/JNK signaling associated 
with EAM. Recently we reported that olmesartan im-
proved  cardiac  function  and  attenuated  cardiac  re-
modeling (fibrosis and hypertrophy) and inflamma-
tory mediators in rats with dilated cardiomyopathy 
after EAM [19]. In the current study, we have exam-
ined  the  effects  of  olmesartan  on  cardiac  function, 
oxidative  stress,  ER  stress,  inflammatory  cytokines 
and MAPK/JNK signaling pathways associated with 
EAM  in  rats.  Our  results  strongly  suggest  that 
olmesartan protects against EAM in rats, at least in 
part via suppression of oxidative stress, ER stress and 
inflammatory cytokines. 
Materials and Methods 
Materials 
Olmesartan  was  generously  provided  by 
Daichi-Sankyo  Pharmaceutical  (Tokyo,  Japan),  and 
Lewis rats (male, 8 weeks old) were purchased from 
Charles River Japan Inc., Kanagawa, Japan. 
Experimental design 
All  experiments  were  carried  out  using 
8-week-old male Lewis rats and were performed in 
accordance with the guidelines of our institute [3, 20]. 
Lewis  rats  were  injected  in  the  footpads  with  anti-
gen-adjuvant  emulsion  in  accordance  with  a  proce-
dure  described  previously.  In  brief,  porcine  cardiac 
myosin was dissolved in phosphate-buffered saline at 
5  mg/ml  and  emulsified  with  an  equal  volume  of 
complete freund’s adjuvant with 11 mg/ml Mycobac-
terium  tuberculosis  H37RA  (Difco  Lab.,  Detroit,  MI, 
USA).  EAM  in  rats  was  induced  by  immunization 
with 0.1 ml of emulsion once by subcutaneous injec-
tion into their rear footpads (0.1 ml to each footpad). 
The morbidity of EAM was 100% in rats immunized 
by  this  procedure  [3,  20].  After  immunization,  the 
Lewis rats were divided into two groups and received 
oral  administration  of  olmesartan  (10  mg/kg/day; 
Group-Olm-10) or vehicle (Group-V) for 21 days. Age 
matched Lewis rats without immunization was used 
as normal controls (Group-N). Since fibrosis and in-Int. J. Biol. Sci. 2011, 7 
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flammation  plays  an  important  role  in  myocardial 
remodeling in our EAM model, we have chosen the 
antifibrotic,  anti-inflammatory  and  maximal  hypo-
tensive dose of olmesartan as previously reported [15, 
16, 19, 21]. Moreover, we reported that olmesartan (10 
mg/kg/day) improved cardiac function and attenu-
ated  cardiac  remodeling  (fibrosis  and  hypertrophy) 
and inflammatory mediators in rats with dilated car-
diomyopathy after EAM [19]. 
Hemodynamic and echocardiographic studies 
To  obtain  hemodynamic  data,  rats  were  anes-
thetized with 2% halothane in oxygen during the sur-
gical  procedures.  A  catheter-tip  transducer  (Miller 
SPR  249;  Miller  Instruments,  Houston,  TX)  was  in-
serted into the left ventricle through the right carotid 
artery for the determination of peak left ventricular 
pressure  (LVP)  and  left  ventricular  end-diastolic 
pressure  (LVEDP),  and  the  rates  of  intraventricular 
pressure rise (+ dP/dt) and decline (    dP/dt) were 
recorded  as  described  previously  [20].  After  instru-
mentation,  the  concentration  of  halothane  was  re-
duced to 0.5% to minimize the effects of anesthesia on 
hemodynamic parameters. In addition, systolic blood 
pressure  (SBP)  and  diastolic  blood  pressure  (DBP) 
was measured in conscious rats by using the tail-cuff 
plethysmographic  method  (Softron  BP-98A,  Tokyo, 
Japan).  Echocardiographic  studies  were  carried  out 
with a 7.5-MHz transducer (Aloka Inc., Tokyo, Japan). 
The  left  ventricular  dimensions  in  diastole  (LVDd) 
and systole (LVDs) and percentage fractional short-
ening  (FS)  were  estimated  using  M-mode  measure-
ments.  
Cardiac morphometric parameters 
The  body  weight  (BW)  of  rats  was  noted  just 
before the surgical procedure. After the hemodynamic 
and echocardiographic analyses, the rats were sacri-
ficed, and the whole myocardium was isolated and 
weighed to calculate the ratio of heart weight to body 
weight (HW/BW). 
Histopathology 
The excised wet myocardium was kept in 10% 
formalin  and  the  midventricle  sections  were  then 
embedded  with  paraffin.  Inflammatory  cell  infiltra-
tions  were  identified  using  hematoxylin  and  eosin 
(H&E)-stained  sections  at  200-fold  magnification  by 
light microscopy. Several sections of each heart were 
scored blindly by 2 observers. The scores assigned to 
these  specific  sections  were  averaged  as  described 
previously [22]. The extent of cellular infiltration was 
graded  and  scored  as  follows:  0  (normal),  1  (lesion 
extent  between  10-25%  of  a  transverse  section),  2 
(between  25-50%),  3  (between  50-75%),  and  4  (ex-
ceeding 75%). In addition, the area of myocardial fi-
brosis in the midventricle tissue sections stained with 
Azan-Mallory  was  quantified  using  a  color  image 
analyzer  (CIA-102,  Olympus,  Tokyo,  Japan)  and 
measuring the blue fibrotic areas as opposed to the 
red  myocardium  at  200X magnification.  The  results 
were presented as the ratio of the fibrotic area to the 
whole area of the myocardium [20].  
Analysis of mRNA levels of inflammatory cyto-
kines  
RNA Extraction  
Heart  tissues  were  preserved  by  immersion  in 
RNAlater (Ambion Inc., Austin, TX) immediately af-
ter sampling. The extraction of total  RNA was per-
formed after homogenization by using Ultra TurraxT8 
(IKA Labortechinik, Staufen, Germany) in TRIzol re-
agent (invitrogen Corp., Carlsbad, CA) in accordance 
with the standard protocol. Synthesis of cDNA was 
performed by reverse transcription using total RNA (2 
µg) as a template (Super Script II; Invitrogen Corpo-
ration, Carlsbad, CA).  
Gene expression analysis by real time RT-PCR 
Gene expression analysis was performed by real 
time reverse transcription polymerase chain reaction 
(RT-PCR)  (Smart  Cycler;  Cepheid,  Sunnyvale,  CA) 
using  cDNA  synthesized  from  the  CHF  specimens. 
Primer sequences were as follows: Interleukin (IL)-1β 
(forward),  CTTCAATCTCACAGCAGCACATCTCG, 
(reverse),  TCCACGGGCAAGACATAGGTAGC; 
MCP-1  (forward),  CTCACCTGCTGCTACTCATTC 
ACT, (reverse), TGCTGCTGGTGATTCTCTTGTAGT; 
interferon  (IFN)-γ  (forward), 
GCTTTGCAGCTCTTCCTCAT,  (reverse), 
GTCACCATCCTTTTGCCAGT;  TNF-α  (forward), 
CCCCAAAGGGATGAGAAGTT,  (reverse), 
CACTTGGTGGTTTGCTACGA;  GAPDH  (forward), 
GCTCATTTCCTGGTATGACAACG,  (reverse), 
AGGGGTCTACATGGCAACTG.  Real  time  RT-PCR 
by  monitoring  with  TaqMan  probe  (TaqMan  Gene 
expression  assays;  Applied  Biosystems,  Foster  City, 
CA) was performed in accordance with the following 
protocol: 600 seconds at 95 ºC, followed by thermal 
cycles of 15 seconds at 95 ºC, and 60 seconds at 60 ºC 
for extension. Relative standard curves representing 
several 10 fold dilutions (1:10:100:1000:10,000:100,000) 
of  cDNA  from  heart  tissue  samples  were  used  for 
linear  regression  analysis  of  other  samples.  Results 
were  normalized  to  GAPDH  mRNA  as  an  internal 
control and are thus shown as relative mRNA levels. 
Immunohistochemistry 
Formalin-fixed,  paraffin-embedded  cardiac  tis-Int. J. Biol. Sci. 2011, 7 
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sue  sections  were  used  for  immunohistochemical 
staining.  After  deparaffinization  and  hydration,  the 
slides  were washed in Tris-buffered saline (TBS; 10 
mM/l Tris HCl, 0.85% NaCl, pH 7.5) containing 0.1% 
bovine serum albumin (BSA). Endogenous peroxidase 
activity  was  quenched  by  incubating  the  slides  in 
methanol  and  0.6%  H2O2  in  methanol.  To  perform 
antigen  retrieval,  the  sections  were  pretreated  with 
trypsin for 15 min at 37 °C. After overnight incubation 
with the primary antibody, namely mouse polyclonal 
anti-3-nitrotyrosine  (3-NT)  (Abcam  Inc,  MA,  USA), 
mouse  monoclonal  anti-4-Hydroxynonenal  (4-HNE) 
(Oxis  International,  Portland,  OR)  and  rabbit  poly-
clonal  anti-Ang-II  antibody  (Peninsula  Laboratories 
Inc, San Carlos, California) (diluted 1:100) at 4 °C, the 
slides were washed in TBS and horseradish peroxi-
dase  (HRP)-conjugated  secondary  antibody  (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) was then 
added and the slides were further incubated at room 
temperature for 45 min. The slides were washed in 
TBS  and  incubated  with  diaminobenzidine  tetrahy-
drochloride as the substrate, and counterstained with 
hematoxylin.  A  negative  control  without  primary 
antibody was included in the experiment to verify the 
antibody  specificity.  Measurement  of  myocardial 
immunoreactivity  for  Ang-II  was  performed  in  25 
randomly selected fields in heart sections in 400-fold 
magnification by light microscopy. Ten color images 
of 4-HNE staining were selected from four sections of 
the heart and viewed at 400-fold magnifications. The 
area and intensity of 4-HNE staining were quantified 
by  scoring  in  a  blinded  manner.  The  scoring  range 
was the following: where 0, no visible staining; 1, faint 
staining; 2 moderate staining; and 3, strong staining 
[23]. 
Western Immunoblotting  
The  myocardial  tissue  samples  obtained  from 
different groups were homogenized with lysis buffer. 
Protein concentrations in these homogenized samples 
were measured by the bicinchoninic acid method. For 
Western blots, proteins were separated by SDS-PAGE 
and identified with the following antibodies to quan-
tify the myocardial levels of proteins: goat polyclonal 
anti-p67phox,  anti-gp91phox,  anti-glucose  regulated 
protein 78 (GRP78), anti–glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH),  anti-tumor  necrosis  fac-
tor-α  antibodies;  rabbit  polyclonal  anti-AT1R,  an-
ti-caspase-12,  anti-p47phox,  nuclear  factor  kappa  B 
(NF-κB),  p38  mitogen-activated  protein  kinase  (p38 
MAPK),  phospho-p38  MAPK,  c-Jun  N-terminal  Ki-
nase (JNK), phospho-JNK antibody and mouse poly-
clonal anti-C/EBP homologous protein (CHOP), an-
ti-osteopontin  (OPN)  antibody  (Santa  Cruz  Biotech-
nology, Santa Cruz, CA, USA). We used 10% sodium 
dodecyl  sulfate-polyacrylamide  gel  electrophoresis 
(Bio-Rad,  CA,  USA),  and  electrophoretically  trans-
ferred to nitrocellulose membranes. Membranes were 
blocked with 1% nonfat dry milk and 1% BSA (Sigma, 
St Louis, USA) in TBS-T (20 mM/l Tris, pH 7.6, 137 
mM/l NaCl, and 0.05% Tween). After incubation with 
primary antibody, the bound antibody was visualized 
with  respective  HRP-coupled  secondary  antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
chemiluminescence  developing  agents  (Amersham 
Biosciences,  Buckinghamshire,  UK).  The  level  of 
GAPDH was estimated in every sample to check the 
equal loading of sample. MAPK and JNK activation 
was quantified by normalizing phospho-MAPK and 
phospho-JNK expression level with MAPK and JNK 
expression  in  the  same  sample  respectively.  Films 
were  scanned,  and  band  densities  were  quantified 
with  densitometric  analysis  using  Scion  Image  pro-
gram (GT-X700, Epson, Tokyo, Japan).  
Analysis of cardiac apoptosis by terminal trans-
ferase-mediated dUTP nick-end labeling assays 
The transferase-mediated dUTP nick-end label-
ing (TUNEL) assay was performed as specified in the 
instructions  for  the  in  situ  apoptosis  detection  kit 
(Takara Bio Inc., Shiga, Japan). Sections embedded in 
paraffin were mounted and examined using light mi-
croscopy. Digital photomicrographs were obtained by 
using a color image analyzer (CAI-102, Olympus) at 
X400 magnification, and 25 random fields from each 
heart were chosen and the number of TUNEL positive 
nuclei was quantified in a blinded manner. For each 
group, three sections were scored for apoptotic nuclei. 
Only nuclei that were clearly located in cardiac myo-
cytes were considered. 
Statistical analysis 
All values are expressed as means ± SEM. Statis-
tical analysis of differences between the groups was 
performed by one-way ANOVA, followed by Tukey’s 
or  Bonferroni’s  method  and  two  tailed  t-test  when 
appropriate. A value of P < 0.05 was considered as 
statistically significant.   
Results 
Olmesartan treatment improves myocardial 
function 
Although heart rate was not different among the 
three groups of rats, central venous pressure (CVP) 
and  LVEDP  were  significantly  higher  (6.96±0.8  vs 
0.48±0.2 mm Hg P < 0.01; 21.23±2.2 vs 3.18±6.4 mm 
Hg P < 0.01, respectively) and ±dP/dt were signifi-
cantly lower in vehicle-treated rats than in group N Int. J. Biol. Sci. 2011, 7 
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(2133±219 vs 8004±1462 mm Hg/s P < 0.01; 2003±236 
vs 7958±1320 mm Hg/s P < 0.01, respectively), indi-
cating  systolic  and  diastolic  dysfunction  in  vehi-
cle-treated rats (Table 1). CVP and LVEDP were sig-
nificantly decreased in the olmesartan-treated group 
compared with those in vehicle-treated group. Myo-
cardial contractility parameters were also improved in 
EAM rats treated with olmesartan. In addition, SBP 
and DBP were significantly lowered in vehicle-treated 
rats than in group N rats and were further lowered by 
treatment with olmesartan. 
Echocardiographic studies shown that in group 
V  rats  with  increased  LVDd  and  LVDs  (7.6±0.4  vs 
7.1±0.6 mm P < 0.01; 6.5±0.51 vs 4.0±0.56 mm P < 0.01, 
respectively), and reduced FS (14.4±3.8 vs 44.7±3.3% P 
<  0.01)  and  ejection  fraction  (EF)  (34.2±8.3  vs 
80.6±3.3%  P  <  0.01),  indicating  impaired  systolic 
function compared with that in group N rats (Table 1). 
Treatment  with  olmesartan  significantly  decreased 
LVDd and increased FS and EF compared with those 
in vehicle-treated rats (Table 1). 
 
Table 1. Changes in histopathological, hemodynamic and echocardiographic parameters after 3 weeks of treatment with 
olmesartan in rats with or without EAM 
  Group N(n=6)  Group V(n=8)  Group Olm-10 (n=8) 
Histopathology       
BW (g)  336±6.3  253±5.7**  260±4.1** 
HW (g)  1.02±0.01  1.47±0.04**  0.98±0.04## 
HW/BW (g/kg)  3.1±0.09  5.7±0.44**  4.3±0.20*## 
Cardiac histological score (cellular infiltration)   
0 
 
2.7±0.60 
 
1.0±1.20## 
Area of fibrosis (%)  2.5±0.5  56.75±2.4**  32.5±2.1## 
 
Hemodynamic data 
     
CVP (mmHg)  0.48±0.2  6.96±0.8**  3.67±0.9## 
SBP (mmHg)    121 ± 3   105 ± 10*   92 ± 8* 
DBP (mmHg)     90 ± 5   85 ± 8*   74 ± 9* 
LVEDP (mmHg)  3.18±6.4  21.23±2.2**  7.64±2.5** 
+dP/dt (mmHg/s)  8004±1462  2133±219**  2986±316** 
_dP/dt (mmHg/s)  7958±1320  2003±236**  2408±224** 
HR (beats/min)  352±5.3  306±22.6  299±19.6 
 
Echocardiographic data 
     
LVDd (mm)  7.1±0.6  7.6±0.4  7.1±0.3 
LVDs (mm)  4.0±0.56  6.5±0.51**  4.4±0.3# 
FS (%)  44.7±3.3  14.4±3.8**  39.2±3.3## 
EF (%)  80.6±3.3  34.2±8.3**  74.3±3.7## 
Results are presented as the mean ± SEM. n, no. of rats. BW, body weight; HW, heart weight; HW/BW, ratio of heart weight to body weight; 
CVP, central venous pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEDP, left ventricular end-diastolic pressure; {±} 
dP/dt, rate of intra-ventricular pressure rise and decline; HR, heart rate; LVDd, left ventricular dimension in diastole; LVDs, left ventricular 
dimension in systole; FS, fractional shortening; EF, ejection fraction; group N, aged matched untreated rats; group V, rats with heart failure 
treated with vehicle; group Olm-10, rats with heart failure treated with olmesartan 10 mg/(kg day), respectively; *P < 0.05 and **P < 0.01 vs. 
group N; #P < 0.05 and ##P < 0.01 vs. group V. 
 
Effects of olmesartan on morphometric param-
eters 
HW  and  HW/BW  were  significantly  larger  in 
group V than in group N rats (1.47±0.04 vs 1.05±0.01 g 
P < 0.01; 5.7±0.44 vs 3.1±0.09 g/kg P < 0.01, respec-
tively and Table 1). Olmesartan significantly reduced 
HW  and  HW/BW,  compared  with  those  in  vehi-
cle-treated rats. 
Effects of olmesartan on cellular inflammation 
and inflammatory cytokines  
On  day  21  at  euthanization,  severe  injuries  to 
myocardium with cellular infiltration were observed 
in the myocarditis group. The severity of cellular in-
filtration was significantly reduced in the olmesartan 
group, indicating a significantly reduced severity of 
disease  (Fig  1A  and  Table  1).  In  addition,  RT-PCR 
analyses showed that the expression of IL-1β, MCP-1, 
TNF-α,  and  IFN-γ  mRNA  e  were  significantly  in-
creased in vehicle-treated rats, compared with those 
in group N rats (Fig 1B-E). In contrast, treatment with 
olmesartan  significantly  decreased  the  myocardial 
mRNA  expressions  of  IL-1β,  MCP-1,  TNF-α,  and 
IFN-γ  (1.6,  2.8,  1.9  and  3.8-fold,  respectively)  com-
pared with those in group V rats (Fig 1B-E). In line 
with RT-PCR data, protein expressions of TNF-α and 
NF-κB in the myocardial tissue was significantly in-
creased in group V rats compared with those in group Int. J. Biol. Sci. 2011, 7 
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N rats (Fig 1F-G), and this was significantly attenu-
ated by olmesartan treatment. 
Effects of olmesartan on myocardial fibrosis and 
its marker molecule (OPN)  
The hearts from EAM rats showed massive fi-
brosis and an increased expression of its marker mol-
ecule  (OPN)  compared  to  those  from  group  N  rats 
(Fig 2 A and A1). Treatment with olmesartan signifi-
cantly reduced the percent area of fibrosis and OPN 
expression than in vehicle-treated rats (Fig 2 A and 
A1).  
 
 
 
Figure 1: Effects of olmesartan on cellular infiltration and inflammatory cytokines in rats with EAM induced by autoimmune 
myocarditis. [1A] Histopathology in the heart (H&E-staining) at ×200 fold magnification. (a) Histopathology in a control 
(group N) (grade 0). (b) Representative histopathology in rat with myocarditis treated with vehicle (group V), the myocardial 
inflammation was diffused and exceeding 50% of the transverse section (grade 3). (c) Representative histopathology in rat 
with myocarditis treated with olmesartan (group Olm-10), showed a small focus of cellular infiltration (grade 1). [1B-F] 
Myocardial messenger RNA expression levels of IL-1β [1B], MCP-1 [1C], TNF-α [1D], IFN-γ [1E] and protein expression of 
TNF-α [1F], NF-κB [1G] in rats with EAM was determined by quantitative RT-PCR and Western blot. The mRNA ex-
pression level of each sample was expressed relative to the expression level of GAPDH gene. [1F-1G] Representative 
Western blots showing specific bands for TNF-α, NF-κB and GAPDH as an internal control. Equal amounts of protein 
sample (30 g) obtained from whole ventricular homogenate were applied in each lane. The mean density value of TNF-α, 
NF-κB was expressed as a ratio relative to that of GAPDH. Data are mean ± SEM of 4 to 6 rats. Group N, age-matched 
untreated rats; group V, EAM rats administered with vehicle; group Olm-10, EAM rats treated with olmesartan (10 
mg/kg/day). The values are mean ± SEM. 
*P<0.05, 
**P<0.01 vs group N; 
##P<0.01 vs group V. Int. J. Biol. Sci. 2011, 7 
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Figure 2: Effects of olmesartan on cardiac fibrosis and oxidative stress in rats with EAM induced by autoimmune myo-
carditis. [2A] Azan–Mallory staining for fibrosis of the cross-sectional tissue slices of hearts. Fibrosis is indicated by the blue 
area as opposed to the red myocardium (×200). [2A1] Myocardial protein expression of osteopontin (OPN). Repre-
sentative Western blots showing specific bands for OPN and GAPDH as an internal control. Equal amounts of protein 
sample (30 g) obtained from whole ventricular homogenate were applied in each lane. The mean density value of OPN was 
expressed as a ratio relative to that of GAPDH. [2B, C, D] Immunohistochemistry of 4-hydroxy-2-nonenal (4-HNE), 
3-nitrotyrosine (3-NT) and angiotensin-II [counterstained with hematoxylin; ×400]. Bar graph shows quantitative analysis of 
4-HNE [2B1] and Ang-II positive cardiomyocytes [2D1] in groups N, V and Olm-10. Group N, age-matched untreated rats; 
group V, EAM rats administered with vehicle; group Olm-10, EAM rats treated with olmesartan (10 mg/kg/day). The bar 
value indicates 20 μm. The values are mean ± SEM. 
*P<0.05 and 
**P<0.01 vs group N; 
#P<0.05, 
##P<0.01 vs group V.  
 
 
 
Effects of olmesartan on myocardial 4-HNE and 
3-NT content 
Myocardial staining intensities of 4-HNE, a by-
product of lipid peroxidation, an index of oxidative 
stress, were apparently stronger in the vehicle-treated 
rats compared with that in group N rats. Olmesartan 
treatment  significantly  reduced  the  intensities  of 
4-HNE in EAM rats (Fig 2B and B1). Semi quantifica-
tion  analysis  showed  that  4-HNE  scores  were  also 
increased  in  the  vehicle-treated  group  and  the  in-
crease was attenuated by the treatment of olmesartan 
(Fig 2B and B1). In parallel with increased NADPH 
oxidase subunits (Fig 3B-D), there was an increase in 
peroxynitrite  formation  in  vehicle-treated  rats,  as 
measured by the content of 3-NT in the cardiac tissue 
(Fig  2C).  In  contrast,  myocardial  3-NT  content  was 
significantly  decreased  in  olmesartan  treated  rats 
compared to that in group V. 
Olmesartan attenuate the expression of cardiac 
Ang-II, AT1R and NADPH oxidase subunits 
Ang-II  activates  NADPH-dependent  oxidases 
via  AT1R  stimulation,  the  most  important  vascular 
source of superoxide (O2-). The cardiac expression of 
Ang-II,  AT1R  and  NADPH  oxidase  subunits  were 
significantly higher in group V rats compared with Int. J. Biol. Sci. 2011, 7 
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that shown in group N rats (Figs 2D, D1 and Fig 3), 
and these changes were significantly reversed by the 
treatment with olmesartan (Figs 2D, D1 and Fig 3). 
Effects of olmesartan on myocardial protein ex-
pressions of GRP78, CHOP and Caspase-12 and 
apoptosis 
The protein levels of GRP78, CHOP and caspa-
se-12 in the myocardium were significantly upregu-
lated in group V rats as compared with those in group 
N rats. These levels were significantly attenuated in 
olmesartan treated rats when compared with the ve-
hicle-treated  rats  (Fig  4A-C).  In  addition,  cardiac 
apoptosis is further confirmed by TUNEL assay and 
showed that the numbers of TUNEL positive nuclei 
were significantly higher in myocardial tissue sections 
from  group  V  than  in  group  N  (Fig  4D  and  D1). 
However,  treatment  with  olmesartan  significantly 
decreased  the  number  of  TUNEL  positive  nuclei 
compared to that in group V (Fig 4D and D1).  
 
 
Figure 3: Effects of olmesartan on myocardial protein expressions of AT1R, p47phox, p67phox, and gp91phox. [3A-D] 
Representative Western blots showing specific bands for AT1R, p47phox, p67phox, gp91phox and GAPDH as an internal 
control. Equal amounts of protein sample (30 g) obtained from whole ventricular homogenate were applied in each lane. 
These bands are representative of four separate experiments. 3A–D, Densitometric data of protein analysis. The mean 
density value of AT1R, p47phox, p67phox and gp91phox was expressed as a ratio relative to that of GAPDH. Each bar 
represents mean ± SEM of 4 to 6 rats. Group N, age-matched untreated rats; group V, EAM rats administered with vehicle; 
group Olm-10, EAM rats treated with olmesartan (10 mg/kg/day). The values are mean ± SEM. 
**P<0.01 vs group N; 
#P<0.05, 
##P<0.01 vs group V. Int. J. Biol. Sci. 2011, 7 
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Figure 4: Effects of olmesartan on myocardial protein expressions of GRP78, CHOP, caspase-12 and apoptosis. [4A-C], 
Representative Western blots showing specific bands for GRP78, CHOP, caspase-12 and GAPDH as an internal control. 
Equal amounts of protein sample (30 g) obtained from whole ventricular homogenate were applied in each lane. These 
bands are representative of three separate experiments. 4A-C, Densitometric data of protein analysis. The mean density 
value of GRP78, CHOP and caspase-12 was expressed as a ratio relative to that of GAPDH. [4D] Myocardial tissue sections 
stained for TUNEL-positive apoptotic nuclei (indicated by arrows) in the hearts of myosin-immunized rats (×400). [4D1] Bar 
graph shows quantitative analysis of TUNEL positive cells. Each bar represents mean ± SEM of 4 to 6 rats. Group N, 
age-matched untreated rats; group V, EAM rats administered with vehicle; group Olm-10, EAM rats treated with olmesartan 
(10 mg/kg/day). The values are mean ± SEM. 
**P<0.01 vs group N; 
#P<0.05, 
##P<0.01 vs group V. Int. J. Biol. Sci. 2011, 7 
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Figure 5: Myocardial expressions of phospho-p38 MAPK, phospho-JNK family proteins. [5A-B] Representative western 
blots showing specific bands for phospho-p38 MAPK, phospho-JNK, p38 MAPK and JNK as an internal control. Equal 
amounts of protein sample (30 g) obtained from whole ventricular homogenate were applied in each lane. These bands are 
representative of four separate experiments. 5A-B, Densitometric data of protein analysis. The mean density value of 
phospho-p38 MAPK and phospho-JNK was expressed as a ratio relative to that of p38 MAPK and JNK. Each bar represents 
mean ± SEM of 4 to 6 rats. Group N, age-matched untreated rats; group V, EAM rats administered with vehicle; group 
Olm-10, EAM rats treated with olmesartan (10 mg/kg/day). The values are mean ± SEM. 
**P<0.01 vs group N; 
#P<0.05 vs 
group V. 
 
Effects of olmesartan on myocardial protein ex-
pressions of MAPK and JNK 
Myocardial  protein  expression  of  phospho-p38 
MAPK,  phospho-JNK  was  markedly  increased  in 
group V rats compared with that in group N rats (Fig 
5A and 5B) and this was significantly attenuated by 
olmesartan treatment (Fig 5A and 5B).  
Discussion  
The results of the present study demonstrate that 
the  treatment  with  oral  olmesartan  improved  both 
systolic  (+dP/dt,  %  EF  and  %  FS)  and  diastolic 
(−dP/dt and LVEDP) functions and reduced the se-
verity of acute EAM in rats, and that the cardiopro-
tection of olmesartan occurs  at least in part  via the 
suppression  of  oxidative  stress,  endoplasmic  reticu-
lum (ER) stress and inflammatory cytokines in addi-
tion to hemodynamic modifications. 
Proinflammatory cytokines are capable of mod-
ulating  cardiovascular  function  by  various  mecha-
nisms. Several clinical studies have described the par-
ticipation of proinflammatory cytokines in the path-
ogenesis of cardiac diseases. The levels of circulating 
proinflammatory  cytokines  such  as  tumor  necrosis 
factor (TNF)-α and IL-1 and IL-6 are elevated in pa-
tients  with  myocarditis  [24].  In  a  murine  model  of 
viral  myocarditis,  the  intracardiac  expression  of 
TNF-α,  IL-1β,  interferon-γ,  and  IL-2  genes  were  in-
creased [25]. The degree of expression was correlated 
with the severity of the disease, which suggests that 
the overproduction of proinflammatory cytokines and 
chemokines may aggravate the disease. This is sup-
ported in part by recent reports that the over expres-
sion of TNF-α in heart caused severe myocarditis and 
cardiomyopathy  in  transgenic  mice  [26],  and  that 
IL-1β as well as TNF-α promoted the aggravation of 
viral  myocarditis  in  virus-resistant  mice  [27].  It  has 
been  reported  that  Ang-II  induces  inflammation 
through  the  production  of  inflammatory  cytokines, 
reactive  oxygen  species  (ROS),  and  adhesion  mole-
cules [28]. Studies reported that AT1R antagonists are 
reported to  suppress cytokine production and tran-
scription of cytokine genes in vitro and in vivo [13, 15, 
16, 19, 29-31]. Interestingly, we could observe an in-
crease in the myocardial mRNA levels of inflamma-
tory  cytokines  such  as  TNF-α,  MCP-1,  IL-1β,  and 
IFN-γ  and  protein  levels  of  TNF-α,  NF-κB  and  in-
creased  inflammatory  cell  infiltration  in  rats  with 
EAM, and these changes in mRNA and protein levels 
were significantly decreased by olmesartan treatment 
(Fig 1).  
Ang-II  contributes  to  cardiac  remodeling,  hy-
pertrophy, fibrosis and LV dysfunction. Accumulat-
ing evidence suggests that many of the adverse car-
diac effects of Ang-II are triggered by redox cycling of 
ROS,  generated  in  part  by  an  NADPH  oxi-
dase-dependent  pathway  [32-35],  and  NADPH  oxi-
dase is one of the major sources of Ang-II-mediated 
ROS  in  ventricular  myocytes.  NADPH  oxidase  is  a Int. J. Biol. Sci. 2011, 7 
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multicomponent enzyme complex that is composed of 
the  membrane-bound  heterodimer  gp91phox  (phox 
indicates  phagocytic  oxidase;  NOX2)  and  its  homo-
logue NOX4; p22phox; the cytosolic regulatory subu-
nits p40phox, p47phox, and p67phox; and the small 
GTP-binding protein, Rac1 [36, 37]. NADPH oxidase 
catalyzes the 1-electron reduction of molecular oxy-
gen to superoxide anion, which can react with nitric 
oxide to form short-lived peroxynitrite. Peroxynitrite 
then forms stable 3-NT conjugated molecules, which 
may be used as a marker of oxidative stress [36]. ROS 
derived from NADPH oxidase activation have been 
shown to play a critical role in hypertrophy, fibrosis, 
and remodeling in the heart and vasculature [36-38]. 
The activation of NADPH oxidase is also documented 
in pressure overload-induced LV hypertrophy in mice 
[39]. Further, increase in the expression of NADPH 
oxidase subunits such as gp91phox and p22phox are 
found  in  the  infarcted  rat  and  human  myocardium 
[14,  40].  It  has  been  reported  that  AT1R  antagonist 
synergistically  attenuate  atherosclerosis,  diastolic 
heart failure, diabetes and murine myocarditis at least 
partly via inhibition of oxidative stress [14, 30, 31]. In 
the present study, we confirmed the Ang-II induced 
ROS  activation  in  remodeling  LV  myocardium  of 
EAM  rats  by  several  independent  indices  such  as 
immunohistological  and  western  immunoblotting 
detection of Ang-II expression, protein oxidation (i.e., 
4-HNE),  superoxide  formation  measured  by  3-NT 
staining  and  increased  expression  of  AT1R  and 
NADPH oxidase subunits (Fig 2B-D and Fig 3A-D), 
respectively.  These  changes  were  significantly  re-
versed  by  treatment  with  olmesartan  in  EAM  rats. 
Our present data may link the involvement of Ang-II 
in  LV  remodeling  process  via,  at  least  in  part,  a 
pathway  of  Ang-II  induced  ROS  activation.  On  the 
basis of our results, we consider that olmesartan pro-
tects the heart from EAM partly through the suppres-
sion of inflammatory cytokines and oxidative stress in 
addition to hemodynamic modifications. 
Structural alterations, such as progressive myo-
cardial  hypertrophy  and  fibrosis,  are  considered  a 
pathological  basis  for  the  development  of  diastolic 
dysfunction [41], and the RAS is suggested to play a 
pivotal role in the progression of myocardial changes 
[31, 42] therefore, therapy aiming at reversing myo-
cardial  remodeling  should  be  attempted  to  prevent 
progression to heart failure. Further, the expression of 
the  inflammatory  chemokine  osteopontin  (OPN)  is 
dramatically  increased  in  cardiomyocytes  and  in-
flammatory cells during myocarditis and heart failure 
in human and animals [43-46] and its high expression 
levels in acute myocarditis are associated with con-
secutive development of extensive fibrosis [43]. Stud-
ies have demonstrated that Ang-II upregulated car-
diac fibrosis and its marker molecule (OPN) expres-
sion [43, 47-49] and OPN deficiency could abolish the 
development of Ang-II-induced cardiac fibrosis [48] 
suggest that OPN had a pivotal role in the mitogenic 
effect  of  Ang-II  on  rat  cardiac  fibroblasts.  Previous 
studies have reported that AT1R antagonist is protec-
tive against LV fibrosis [13, 19, 31, 43, 46, 49], and de-
creases OPN expression in non-infarcted myocardium 
[47] in turn prevents cardiac remodeling. In line with 
the previous reports [31, 43-48], we could also observe 
an increased myocardial fibrosis and its marker mol-
ecule expression (Fig 2A and A1) in the hearts of EAM 
rats. The area of fibrosis was significantly lower in the 
olmesartan-treated rats than in the untreated rats, and 
the decrease in the area of fibrosis was associated with 
the  decreased  OPN  expression.  Thus,  ARB-induced 
regression of LV fibrosis through the suppression of 
OPN expression may therefore be another mechanism 
of the therapeutic effects. 
One histological finding characteristic of failing 
hearts  is  morphological  development  of  the  endo-
plasmic reticulum (ER), suggesting that ER overload 
occurs in this condition [50]. Oxidative stress, hypox-
ia,  and  enhanced  protein  synthesis  in  failing  hearts 
could all potentially enhance ER stress. Emerging data 
has  indicated  that  excessive  and/or  prolonged  ER 
stress leads to the initiation of the apoptotic processes 
promoted by transcriptional induction of CHOP or by 
the  activation  of  c-Jun-N-terminal  kinase  (JNK) 
and/or caspase-12-dependent pathway [51]. Recently, 
the  unfolded  protein  response  (UPR)  and/or 
ER-initiated  apoptosis  have  been  implicated  in  the 
pathophysiology of various human diseases, includ-
ing  cardiovascular  diseases  such  as  cardiac  hyper-
trophy,  heart  failure,  autoimmune  cardiomyopathy, 
atherosclerosis, and ischemic heart disease [52-56]. In 
addition,  authors  have  shown  a  marked  increased 
expression  of  ER  chaperones  such  as  GRP78,  sug-
gesting  that  UPR  activation  is  associated  with  the 
pathophysiology of heart failure in humans and ani-
mals [52, 57]. On the other hand, it has been reported 
that Ang-II upregulated ER chaperones and induced 
apoptosis in cultured adult rat cardiac myocytes [52]. 
Studies have also shown that cardiac myocyte apop-
tosis itself is one of the mechanisms of the progression 
of EAM [60, 61]. Apoptotic death of cardiomyocytes 
and  infiltrating  T  lymphocytes  occurs  in  rat  hearts 
with myosin-induced autoimmune myocarditis, sug-
gesting that apoptosis plays a role in the pathogenesis 
of myocardial injury in myocarditis [58]. The antago-
nism of AT1R receptor prevented upregulation of ER 
chaperones, apoptosis in failing hearts and protects 
the heart against LV remodeling by inhibiting apop-Int. J. Biol. Sci. 2011, 7 
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tosis and improves cardiac function [52, 60, 61]. We 
also investigated ER stress in our model and found 
that myocardial expression of GRP78, CHOP, caspa-
se-12 and number of TUNEL positive cells were sig-
nificantly increased in vehicle-treated EAM rats (Fig 
4) and these levels were significantly attenuated by 
treatment with AT1R blocker olmesartan. These find-
ings suggest that cardiac ER stress is induced via an 
angiotensin  II  type  1  receptor-dependent  pathway. 
Although it is likely that one of the potential mecha-
nisms by which angiotensin II induced ER stress is 
enhanced  protein  synthesis,  further  investigation 
about  the  intracellular  signaling  pathway  by  which 
angiotensin II induces ER stress will be needed. 
Excessive  ER  stress  and  oxidative  stress  can 
trigger the activation of multiple signaling pathways 
such  as  phosphorylation  of  p38  MAPK  and  JNK, 
which are closely associated with cell death [62, 63]. 
Recent studies have demonstrated that the p38 MAPK 
and JNK pathways are activated in an EAM animal 
model [64, 65]. Moreover, MAPKs are important me-
diators of the intracellular signal transduction path-
ways that are responsible for cell growth and differ-
entiation. Further, the activation of MAPK pathways 
is a characteristic finding in heart disease and plays a 
key role in the progression to heart failure which is 
mediated via Ang-II dependent mechanisms [66-68]. 
Our data confirms the activation of myocardial MAPK 
pathways (as assessed by the phosphorylated levels of 
these kinases) in EAM rats and olmesartan treatment 
reduces the activation of p38MAPK, and JNK (Fig 5), 
which suggest that MAPK signaling by stress signal-
ing mediated via Ang II. 
In  the  light  of  these  findings,  present  study 
supports  the  hypothesis  that  olmesartan  improved 
cardiac  function,  and  attenuated  cardiac  oxidative 
stress,  ER  stress,  inflammatory  cytokines  and 
MAPK/JNK  activation  providing  further  evidence 
that Ang-II plays a pivotal role in the myocardial re-
modeling in rats with heart failure after EAM. How-
ever, additional experiments will help to reveal the 
detailed mechanism of action of olmesartan in heart 
failure after EAM. 
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